From f31c21faa1453181663f92d2169bda83c418d981 Mon Sep 17 00:00:00 2001
From: speed-vm <77046757+speed-vm@users.noreply.github.com>
Date: Tue, 1 Oct 2024 14:22:37 +0100
Subject: [PATCH] Update doacs_nhse.json

Text edits
---
 .../measures/definitions/doacs_nhse.json           | 14 +++++++-------
 1 file changed, 7 insertions(+), 7 deletions(-)

diff --git a/openprescribing/measures/definitions/doacs_nhse.json b/openprescribing/measures/definitions/doacs_nhse.json
index ac7b8248e..e5d61c41a 100644
--- a/openprescribing/measures/definitions/doacs_nhse.json
+++ b/openprescribing/measures/definitions/doacs_nhse.json
@@ -1,14 +1,14 @@
 {
   "name": "Proportion of Direct Acting Oral Anticoagulants (DOACs) not prescribed as generic rivaroxaban or generic apixaban tablets",
-  "title": "Percentage DOACs items not prescribed as generic rivaroxaban or generic apixaban tablets",
-  "description": "Percentage DOACs items not prescribed as generic rivaroxaban or generic apixaban tablets",
+  "title": "Percentage DOAC items not prescribed as generic rivaroxaban or generic apixaban tablets",
+  "description": "Percentage DOAC items not prescribed as generic rivaroxaban or generic apixaban tablets",
   "numerator_short": "DOAC items not prescribed as generic rivaroxaban or generic apixaban tablets",
-  "denominator_short": "DOACs items",
+  "denominator_short": "DOAC items",
   "y_label": "Percentage DOACs not prescribed as generic rivaroxaban or generic apixaban tablets",
   "why_it_matters": [
     "In September 2024 the NHS in England released <a href='https://www.england.nhs.uk/long-read/commissioning-recommendations-for-national-procurement-for-doacs/' target='_Blank'>",
     "updated commissioning regulations for DOACs,</a> which state:</p>",
-    "<p><i>For patients commencing treatment for Atrial Fibrillation (AF): subject to the criteria specified in the relevant NICE technology appraisal guidance, clinicians should use ",
+    "<p><i>For patients commencing treatment for atrial fibrillation (AF): subject to the criteria specified in the relevant NICE technology appraisal guidance, clinicians should use ",
     "the best value DOAC that is clinically appropriate for the patient. </p>",
     "<p>Table 1 provides the available DOACs ranked from highest to lowest best value according to the September 2024 and confidential framework prices.",
     "If the highest ranked best value DOAC (generic apixaban or generic rivaroxaban) is contraindicated or not clinically appropriate for the specific patient then, subject to the criteria ",
@@ -25,8 +25,8 @@
     "<tbody>",
     "  <tr>",
     "    ",
-    "    <td style='padding: 10px;'><b>1 (Best value)</b></td>",
-    "    <td style='padding: 10px;'><b>generic rivaroxaban<br>generic apixaban</td>",
+    "    <td style='padding: 10px;'><b>1 (Joint best value)</b></td>",
+    "    <td style='padding: 10px;'><b>Rivaroxaban (generic)<br>Apixaban (generic)</td>",
     "    <td style='padding: 10px;'><b>Best value once a day treatment<br>Best value twice a day treatment</b></td>",
     "  </tr>",
     "  <tr>",
@@ -54,7 +54,7 @@
     "</ul>",
     "</p>",
     "<p>The <a href='https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/#9-identifying-patients-with-atrial-fibrillation-and-using-best-value-direct-acting-oral-anticoagulants' target='_Blank'>",
-    "NHS England National Medicines Optimisation Opportunities for 2024/25</a> identify using best value direct-acting oral anticoagulants as an area for improvement.</p>",
+    "NHS England National Medicines Optimisation Opportunities for 2024/25</a> also identify using best value direct-acting oral anticoagulants as an area for improvement.</p>",
     "<p><b>Please note:</b> OpenPrescribing.net measures have a consistent way of visualising measures, where 'lower is better' ",
     "and therefore in this case we show the proportion of DOACs which are NOT prescribed as edoxaban or generic apixaban tablets.  There are also other oral formulations of generic DOACs recently introduced onto the market.",
     "We do not consider these to be as cost-effective, and they are not considered as first-line in this measure."